YUTREPIA

Launch

treprostinil

NDAINHALATIONPOWDER
Approved
May 2025
Lifecycle
Launch
Competitive Pressure
0/100
Clinical Trials
20

Clinical Trials (5)

NCT07234032Phase 3Not Yet Recruiting

An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Started Apr 2026
344 enrolled
Pulmonary HypertensionInterstitial Lung Disease
NCT07179380Phase 3Recruiting

Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Started Jan 2026
344 enrolled
Pulmonary HypertensionInterstitial Lung Disease
NCT07116681Phase 1Not Yet Recruiting

Effects of Inhaled Treprostinil on Exercise Performance in Exercise Induced Pulmonary Hypertension

Started Oct 2025
8 enrolled
Pulmonary Hypertension
NCT07037836Phase 2Recruiting

Inhaled Treprostinil (Tyvaso Nebulizer) For COPD Patients With Hypoxemia

Started Sep 2025
10 enrolled
COPD (Chronic Obstructive Pulmonary Disease)Hypoxemia
NCT07102316Phase 1Completed

A Study to Assess the Relative Bioavailability After a Single Inhalation Administration of Treprostinil Palmitil Inhalation Powder (TPIP) Formulation 2 (F2) to TPIP Formulation 3 (F3) in Healthy Participants

Started Aug 2025
42 enrolled
Healthy Volunteers

Loss of Exclusivity

LOE Date
May 5, 2037
136 months away
Patent Expiry
May 5, 2037
Exclusivity Expiry
May 23, 2028

Patent Records (5)

Patent #ExpiryTypeUse Code
10898494
May 5, 2037
U-4200
11660304
May 5, 2037
U-4200
11712442
May 5, 2037
U-4200
11744835
May 5, 2037
Product
11744836
May 5, 2037
Product